T1	intervention 28 44	N-acetylcysteine
T2	condition 83 123	paclitaxel-induced peripheral neuropathy
T3	total-participants 442 444	75
T4	eligibility 445 526	breast cancer patients receiving adjuvant paclitaxel 80 mg/m2 weekly for 12 weeks
T5	control 663 676	control group
T6	outcome-Measure 733 770	incidence of different grades of PIPN
T9	outcome 1196 1243	incidence of grade (2, 3) peripheral neuropathy
T10	iv-bin-percent 1292 1297	28.6%
T12	cv-bin-percent 1361 1365	100%
T13	outcome 1418 1437	mTNS and QOL scores
T11	iv-bin-percent 1331 1336	61.9%
T7	outcome 1581 1600	levels of serum NGF
T8	outcome 1634 1652	level of serum MDA
T14	outcome-Measure 895 911	severity of PIPN
T15	outcome-Measure 958 979	quality of life (QOL)
T16	outcome-Measure 1092 1123	serum nerve growth factor (NGF)
T17	outcome-Measure 1129 1156	serum malondialdehyde (MDA)
